Molecular analysis of a recurrent glioblastoma treated with bevacizumab.

摘要: We treated a case of recurrent glioblastoma (GBM) with bevacizumab and assessed its effect biologically. A 55-year-old man left frontal lobe GBM was experiencing recurrence 7 months postoperation. administered concomitant temozolomide (TMZ). Follow-up magnetic resonance imaging (MRI) showed dramatic but temporal tumor reduction; however, the patient died re-recurrent disease 6 months after beginning bevacizumab. obtained an autopsy analyzed detailed molecular change. In specimen, quantity microvessels significantly reduced. Vascular endothelial growth factor receptor (VEGFR) 1 VEGFR2 were downregulated, most likely due to negative feedback mechanism by blocking VEGF signaling. Matrix metalloproteinase (MMP)-2 membrane-type MMP upregulated, resulting in higher activation MMP-2 specimen. MIB-1 staining index phosphorylation levels p44/42-mitogen-activated protein kinase did not change, whereas phosphorylated B (Akt) decreased suggesting compensation and/or amplification other proliferative signaling pathways such as suppression apoptosis Consequently, might inhibit autocrine loop, which then causes change expression related only enhancement invasion also maintenance proliferation.